Management of Anaphylaxis During the SARS-CoV-2 Pandemic

Area of Science:

• Allergy and Immunology
• Public Health
• Infectious Disease

Background:

• The SARS-CoV-2 pandemic necessitated significant changes in healthcare delivery, including increased reliance on telemedicine.
• Restricted access to healthcare facilities required a reevaluation of acute medical care paradigms, particularly for conditions like anaphylaxis.

Purpose of the Study:

• To identify a treatment strategy for anaphylaxis that balances the risks and benefits of emergency department (ED) versus home management during the COVID-19 pandemic.
• To provide guidance for physicians and patients in adapting anaphylaxis care in the context of a global health crisis.

Main Methods:

• This review synthesizes current recommendations and expert opinion on anaphylaxis management during the pandemic.
• It emphasizes the role of telemedicine in shared decision-making and developing individualized anaphylaxis action plans.

Main Results:

• Telemedicine facilitates shared decision-making, enabling personalized anaphylaxis management plans.
• Home management is recommended for mild anaphylaxis symptoms, with ED care reserved for patients with a history of severe or near-fatal episodes.
• Standard anaphylaxis protocols, including prompt epinephrine use, allergen avoidance, and autoinjector preparedness, remain crucial.

Conclusions:

• Anaphylaxis management during the SARS-CoV-2 pandemic requires a nuanced approach, considering local infection rates and patient-specific factors.
• Integrating telemedicine into shared decision-making empowers patients and optimizes care, ensuring safety and minimizing exposure risks.
• Continued adherence to established anaphylaxis prevention and treatment guidelines is essential.